R&D Pipeline
Innovation R&D Pipeline
Potential of our proprietary technology platform to be expanded into more research and therapeutic areas in the near future.
Therapeutic Area Program Target Modality Indication Discovery Preclinical Phase l Phase ll
Oncology
ALK201 FGFR2b ADC GC,SqNSCLC & Solid Tumors
ALK202 EGFR/c-MET BsADC NSCLC,CRC & Solid Tumors
ALK101 EGFR/c-MET BsAb NSCLC,CRC & HNSCC
ALKN501 Undisclosed MsAb Solid Tumors
ALKN206 Undisclosed ADC CRC,PDAC
ALKN207 Undisclosed BsADC Prostate Cancer
ALKN302 Undisclosed TCE Prostate Cancer
Immunology
ALKN403 Undisclosed BsAb IBD,PsA
Leveraging our powerful technology platform to drive continuous expansion of innovative pipeline